替勃龙联合更年灵治疗围绝经期综合征疗效观察  被引量:5

Clinical observation of the therapeutic effect of tibolone combined with gengnianling on perimenopausal syndrome

在线阅读下载全文

作  者:侯雯莅 王新英[1] 

机构地区:[1]河北省保定市妇幼保健院妇保科,071000

出  处:《河北医药》2009年第8期920-922,共3页Hebei Medical Journal

摘  要:目的了解替勃龙联合更年灵胶囊治疗围绝经期综合征的临床疗效和安全性。方法将我院120例患者随机分成2组各60例:观察组口服替勃龙1.25 mg,1次/d,配合更年灵每次1粒,3次/d。对照组口服替勃龙1.25 mg,1次/d。3个月为1疗程。治疗前后B型超声了解子宫内膜情况,检查肝、肾功能、血清E2水平,乳腺情况。Kupperman评分每月1次。结果2组用药后围绝经期症状均明显改善。观察组控制围绝经期症状的疗效优于对照组(P<0.05),且不良反应低。治疗后血清E2水平观察组高于对照组(P<0.05)。子宫内膜厚度治疗前后无明显变化(P>0.05)。结论小剂量替勃龙联合更年灵胶囊能有效地控制围绝经期症状且安全可靠。Objective To observe the therapeutic effect and safety of tibolone combined with gengnianling capsule on perimenopausal syndrome. Methods 120 patients with perimenopansal syndrome were randomly divided into two groups who were enrolled from Dec 2006 to Dec 2007 in our hospital. The 60 patients received tibolone 1.25mg once a day combined with gengnianling capsule 1 pill each time , 3 times a day. The other 60 patients received tibolone 1.25 mg once a day, with a treatment course of 3 months for both groups. The thickness of endometrium was measured by B-ultrasonography. The levels of F2, liver and kidney function and mammary gland state were examined, and Kupperman scoring was performed once a month before and after treatment. Results After treatment, the symptoms of perimenopause were significantly improved in both groups . The observation group who control the symptoms of perimenopause were much better than the contrast group. The level of E2 of the observation group was much higher than the contrast group( P 〈 0.05). The thickness of endometrium of two groups were no change in per-and pest therapy. Conclusion The low-dose tibolone combined with gengnianling capsule can relieve the symptoms of perimenopausal syndrome, with safety and reliability.

关 键 词:替勃龙 更年灵 治疗 围绝经期综合征 

分 类 号:R271.116[医药卫生—中医妇科学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象